NT5E, also known as CD73 or ecto-5'-nucleotidase, is a membrane-bound glycoprotein that functions as an ectoenzyme. It catalyzes the conversion of extracellular adenosine monophosphate (AMP) to adenosine, a key immunosuppressive molecule in the tumor microenvironment. This enzyme plays a critical role in purine metabolism and is expressed in various cell types, including immune cells (T cells, B cells), endothelial cells, and cancer cells. Its overexpression in multiple cancers (e.g., melanoma, breast, lung) correlates with tumor progression, immune evasion, angiogenesis, and metastasis by elevating adenosine levels that suppress anti-tumor T-cell responses via A2A adenosine receptor signaling.
NT5E antibodies are therapeutic tools designed to block CD73 enzymatic activity or disrupt its protein-protein interactions. By inhibiting adenosine production, these antibodies aim to counteract immunosuppression, enhance anti-tumor immunity, and synergize with checkpoint inhibitors (e.g., anti-PD-1/PD-L1). Several monoclonal antibodies (e.g., oleclumab, CPI-006) have entered clinical trials, showing potential in reducing tumor growth and improving immune infiltration. Challenges include managing compensatory pathways, biomarker identification, and minimizing off-target effects. Research continues to optimize antibody specificity, combination strategies, and patient stratification for precision oncology applications.